RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill metastatic cancer cells. Interferon alfa may interfere with the growth of the cancer cells. Combining interleukin-2 and interferon alfa may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 plus interferon alfa in treating adults with metastatic cancer.
OBJECTIVES: I. Determine the response rate, failure-free survival, and overall survival of interleukin-2 and interferon alpha administered subcutaneously on an outpatient basis for 8 weeks to patients with metastatic cancer. II. Determine the toxicities associated with this therapy. OUTLINE: Biological Response Modifier Therapy. Interleukin-2 (Cetus), IL-2, NSC-373364; Interferon alpha (Schering), IFN-A, NSC-377523. PROJECTED ACCRUAL: Up to 30 patients with various malignancies will be entered.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
Bloomington Hospital
Bloomington, Indiana, United States
St. Vincent Hospital and Health Care Center Research Department
Indianapolis, Indiana, United States
Bergan Mercy Medical Center
Omaha, Nebraska, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Baptist Regional Cancer Center - Knoxville
Knoxville, Tennessee, United States